Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
23
pubmed:dateCreated
2004-12-8
pubmed:abstractText
To evaluate the efficacy and toxicity of a novel combination chemotherapeutic regimen including cisplatin with an oral anticancer agent, S-1 that consisted of tegafur, 5-chloro-2, 4-dihydroxypyridine, and potassium oxonate, for non-small-cell lung cancer (NSCLC) patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
7860-4
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15585618-Adenocarcinoma, pubmed-meshheading:15585618-Administration, Oral, pubmed-meshheading:15585618-Adult, pubmed-meshheading:15585618-Aged, pubmed-meshheading:15585618-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:15585618-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:15585618-Carcinoma, Squamous Cell, pubmed-meshheading:15585618-Cisplatin, pubmed-meshheading:15585618-Drug Administration Schedule, pubmed-meshheading:15585618-Drug Combinations, pubmed-meshheading:15585618-Female, pubmed-meshheading:15585618-Humans, pubmed-meshheading:15585618-Lung Neoplasms, pubmed-meshheading:15585618-Male, pubmed-meshheading:15585618-Middle Aged, pubmed-meshheading:15585618-Neoplasm Staging, pubmed-meshheading:15585618-Oxonic Acid, pubmed-meshheading:15585618-Pyridines, pubmed-meshheading:15585618-Survival Rate, pubmed-meshheading:15585618-Tegafur, pubmed-meshheading:15585618-Treatment Outcome
pubmed:year
2004
pubmed:articleTitle
S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial.
pubmed:affiliation
Department of Thoracic Oncology, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku Fukuoka, Japan. yichinos@nk-ml.go.jp
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II